Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-29 22:50:34 - browse：1

Adobe

You didn’t need machine learning to make one prediction about the year’s biggest conference for health care investors, which was held in San Francisco last week. It was going to rain.

Recursion, a biotechnology firm that uses machine learning for drug development and that was announcing that it is rolling out AI-driven drug discovery software with tech giant Nvidia, decided to seize the moment. As the heavens opened, Recursion employees handed out black umbrellas emblazoned with the Recursion logo and lined with neon images of cells. It was one of a series of publicity grabs from the company, including a satellite event featuring Nvidia’s famous CEO, Jensen Huang, who has become a Wall Street rock star as his company’s stock has exploded due to rising expectations for AI, reaching a $1 trillion market value, the sixth highest in the world.

Seeing the square outside the Westin St. Francis, where the J.P. Morgan Healthcare Conference has been held for 42 years, fill with Recursion’s umbrellas was a little like seeing the message that AI was ready for its debut come to life. But it was also true that not everyone was ready to embrace that message.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

WSS

Gilead might be held responsible for not developing a drug

Industry veterans launch new biotech VC with $310M

Report cites 'urgent' need to recruit more diverse clinical trial participants

Bernie Sanders gets little from pharma CEOs on drug prices

Why Eli Lilly’s earnings didn’t quite live up to the hype

Medicare threatens to cut off funding for HCA's Mission hospital

explore

Wikipedia

focus

As demand for Covid shots wanes, Moderna seeks its next success

A disappointing year of Humira biosimilars

Trump demands the U.S. pay no more for drugs than other countries … again

Artificial intelligence use in health care faces greater scrutiny in 2024

Supreme Court strikes down use of affirmative action

Gilead might be held responsible for not developing a drug

At least 13 dead in Texas as scorching temps continue

A disappointing year of Humira biosimilars

Virginia high school admissions case could be legal follow

Here’s what’s in the FDA plan to include pregnant women in clinical trials

explore

Readout LOUD podcast: How biotech is using artificial intelligence

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medical mystery: When a cough is not just a cough

The Readout: Gilead, Bernie Sanders, and other pharma news

Private equity deals in Medicare Advantage declines

knowledge

focus

focus

knowledge